Get the Stockscreener App
3.18
1.27%
0.04
After Hours:
3.16
-0.02
-0.63%
Mural Oncology Plc stock is traded at $3.18, with a volume of 202.11K.
It is up +1.27% in the last 24 hours and down -5.64% over the past month.
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
See More
Previous Close:
$3.14
Open:
$3.3
24h Volume:
202.11K
Relative Volume:
1.36
Market Cap:
$54.25M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-12.64%
1M Performance:
-5.64%
6M Performance:
-2.15%
1Y Performance:
+0.00%
1-Day Range:
$3.10
$3.30
1-Week Range:
$2.87
$3.79
52-Week Range:
$2.87
$6.00
Mural Oncology Plc Stock (MURA) Company Profile
Name
Mural Oncology Plc
Sector
Industry
Phone
353 1 905 8020
Address
10 EARLSFORT TERRACE, DUBLIN 2
Compare MURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MURA
Mural Oncology Plc
|
3.18 | 54.25M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mural Oncology Plc Stock (MURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-04-24 | Initiated | Morgan Stanley | Overweight |
Mural Oncology Plc Stock (MURA) Latest News
2025 will be a big year for Mural Oncology's drugs in development - The Business Journals
BNP Paribas Financial Markets Lowers Stake in Mural Oncology plc (NASDAQ:MURA) - Defense World
Mural Oncology stock hits 52-week low at $2.87 By Investing.com - Investing.com UK
Mural Oncology CEO Caroline Loew sells shares worth $9,394 - Investing.com
Mural Oncology CEO Caroline Loew sells shares worth $9,394 By Investing.com - Investing.com UK
Mural Oncology plc (NASDAQ:MURA) Shares Sold by Verition Fund Management LLC - MarketBeat
Mural Oncology GAAP EPS of -$1.84; reaffirms financial guidance - MSN
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Mural Oncology Awards Key Talent with Stock Options and RSU Inducement Grants - StockTitan
Alkermes to Participate in Upcoming Investor Conferences - Quantisnow
Raymond James Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks - Yahoo Finance
Rodman & Renshaw Initiates Coverage of Mural Oncology (MURA) with Buy Recommendation - MSN
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer - The Manila Times
Mural Oncology's Cancer Drug Shows 33% Response Rate in Melanoma Trial Data | MURA Stock News - StockTitan
HC Wainwright Raises Earnings Estimates for Mural Oncology - Defense World
HC Wainwright Predicts Stronger Earnings for Mural Oncology - MarketBeat
MURAMural Oncology plc Ordinary Shares Latest Stock News & Market Updates - StockTitan
Armistice Capital, LLC Increases Stake in Mural Oncology PLC - GuruFocus.com
Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress - The Manila Times
Mural Oncology plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Mural Oncology Reports 38% Lower Net Loss, Hits Trial Enrollment Milestones in Q3 | MURA Stock News - StockTitan
HC Wainwright Reaffirms "Buy" Rating for Mural Oncology (NASDAQ:MURA) - MarketBeat
Mural Oncology to Participate in Two Upcoming Investor Conferences - The Manila Times
Mural Oncology (MURA) to Present at Major Healthcare Investor Conferences | MURA Stock News - StockTitan
Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - The Manila Times
Mural Oncology Reports Promising Cancer Trial Data, Plans Key 2025 Readouts | MURA Stock News - StockTitan
Vanguard Group Inc's Strategic Reduction in Mural Oncology PLC H - GuruFocus.com
Mural Oncology CFO Adam Cutler sells $25,305 in company stock By Investing.com - Investing.com Canada
Mural Oncology plc (NASDAQ:MURA) CFO Adam D. Cutler Sells 7,421 Shares - MarketBeat
Mural Oncology CFO Adam Cutler sells $25,305 in company stock - Investing.com
Short Interest in Mural Oncology plc (NASDAQ:MURA) Decreases By 15.7% - MarketBeat
HC Wainwright Comments on Mural Oncology Q3 Earnings - MarketBeat
Mural Oncology (NASDAQ:MURA) Coverage Initiated at HC Wainwright - MarketBeat
H.C. Wainwright initiates coverage on Mural Oncology stock with Buy rating - Investing.com UK
167,644 Shares in Mural Oncology plc (NASDAQ:MURA) Bought by Squarepoint Ops LLC - MarketBeat
232,100 Shares in Mural Oncology plc (NASDAQ:MURA) Bought by Renaissance Technologies LLC - MarketBeat
Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - The Manila Times
Raymond James Begins Coverage on Mural Oncology (NASDAQ:MURA) - Defense World
Mural Oncology (NASDAQ:MURA) Coverage Initiated by Analysts at Raymond James - MarketBeat
This MINISO Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Rhumbline Advisers Makes New $34,000 Investment in Mural Oncology plc (NASDAQ:MURA) - Defense World
Point72 Asia Singapore Pte. Ltd. Invests $84,000 in Mural Oncology plc (NASDAQ:MURA) - Defense World
Mural Oncology Highlights Clinical Trials During It's Maiden Investor Day - Forbes
Armistice Capital LLC Takes Position in Mural Oncology plc (NASDAQ:MURA) - Defense World
1,688,000 Shares in Mural Oncology plc (NASDAQ:MURA) Acquired by Armistice Capital LLC - MarketBeat
Mural Oncology's First Virtual Investor Day to Highlight Late-Stage Clinical Progress - The Manila Times
Mural Oncology’s First Virtual Investor Day to Highlight Late-Stage Clinical Progress - StockTitan
Mural Oncology Plc Stock (MURA) Financials Data
There is no financial data for Mural Oncology Plc (MURA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):